csirt@kutim:~/threat-intel/cve/CVE-2026-89426

Katalog CVE

CVSS 8.8 · High EPSS 0,48%

Kerentanan Improper Privilege Management. Skor CVSS 3.1 8.8 (High) menurut wordfence.com.

Deskripsi (NVD)

The Knit Pay – Cashfree, Instamojo, Razorpay, PayPal and more plugin for WordPress is vulnerable to Privilege Escalation in all versions up to, and including, 9.6.1.0. This is due to the `maybe_update_user_role()` function reading the target role directly from an attacker-controlled Gravity Forms entry field — configured via the feed's `user_role_field_id` — and passing it to `WP_User::set_role()` without validating the supplied value against an allowlist of permitted roles. This makes it possible for authenticated attackers, with Subscriber-level access and above, to elevate their privileges to administrator by tampering with the hidden role field value at form submission time. Exploitation is further enabled by the fact that $0 orders are synchronously marked as SUCCESS during form submission without requiring a real payment, and when no GF User Registration user can be resolved, the role assignment target falls back to `$lead['created_by']` — the currently authenticated submitter's own user ID — making any authenticated form submitter an eligible exploitation target.

Rincian

Terbit di NVD
25 September 2026
Terakhir diubah
25 September 2026
Status NVD
Deferred
CVSS 3.1
8.8 (High), sumber wordfence.com
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-269: Improper Privilege Management
EPSS (30 hari)
0,48% peluang dieksploitasi; lebih tinggi dari 39,3% CVE lain

Produk dan versi terdampak

NVD belum mencantumkan data produk (CPE) untuk CVE ini. Produk yang terdampak biasanya disebut di deskripsi dan di advisory vendor pada daftar referensi.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.